The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB s...

Full description

Bibliographic Details
Main Authors:	Masumori, Naoya, Miyamoto, Shintaro, Tsukamoto, Taiji, Furuya, Seiji, Iwasawa, Akihiko, Sato, Takashi, Itoh, Naoki, Shibuya, Akihiko, Oda, Toshiro
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130959/

id	pubmed-3130959
recordtype	oai_dc
spelling	pubmed-31309592011-07-11 The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents Masumori, Naoya Miyamoto, Shintaro Tsukamoto, Taiji Furuya, Seiji Iwasawa, Akihiko Sato, Takashi Itoh, Naoki Shibuya, Akihiko Oda, Toshiro Clinical Study Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment. Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks (P < 0.001)). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin. Hindawi Publishing Corporation 2011 2011-06-28 /pmc/articles/PMC3130959/ /pubmed/21747845 http://dx.doi.org/10.1155/2011/714978 Text en Copyright © 2011 Naoya Masumori et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Masumori, Naoya Miyamoto, Shintaro Tsukamoto, Taiji Furuya, Seiji Iwasawa, Akihiko Sato, Takashi Itoh, Naoki Shibuya, Akihiko Oda, Toshiro
spellingShingle	Masumori, Naoya Miyamoto, Shintaro Tsukamoto, Taiji Furuya, Seiji Iwasawa, Akihiko Sato, Takashi Itoh, Naoki Shibuya, Akihiko Oda, Toshiro The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
author_facet	Masumori, Naoya Miyamoto, Shintaro Tsukamoto, Taiji Furuya, Seiji Iwasawa, Akihiko Sato, Takashi Itoh, Naoki Shibuya, Akihiko Oda, Toshiro
author_sort	Masumori, Naoya
title	The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
title_short	The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
title_full	The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
title_fullStr	The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
title_full_unstemmed	The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
title_sort	efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents
description	Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment. Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks (P < 0.001)). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin.
publisher	Hindawi Publishing Corporation
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130959/
_version_	1611464093037756416

The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

Similar Items